[go: up one dir, main page]

PL1926496T3 - Szczepionka przeciw PCV-2 - Google Patents

Szczepionka przeciw PCV-2

Info

Publication number
PL1926496T3
PL1926496T3 PL06793347T PL06793347T PL1926496T3 PL 1926496 T3 PL1926496 T3 PL 1926496T3 PL 06793347 T PL06793347 T PL 06793347T PL 06793347 T PL06793347 T PL 06793347T PL 1926496 T3 PL1926496 T3 PL 1926496T3
Authority
PL
Poland
Prior art keywords
pcv
vaccine
Prior art date
Application number
PL06793347T
Other languages
English (en)
Inventor
Frank Roerink
Woensel Peter Van
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1926496(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PL1926496T3 publication Critical patent/PL1926496T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06793347T 2005-09-09 2006-09-08 Szczepionka przeciw PCV-2 PL1926496T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05108299 2005-09-09
EP06793347.3A EP1926496B1 (en) 2005-09-09 2006-09-08 Pcv-2 vaccine
PCT/EP2006/066161 WO2007028823A1 (en) 2005-09-09 2006-09-08 Pcv-2 vaccine

Publications (1)

Publication Number Publication Date
PL1926496T3 true PL1926496T3 (pl) 2014-02-28

Family

ID=35482131

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06793347T PL1926496T3 (pl) 2005-09-09 2006-09-08 Szczepionka przeciw PCV-2

Country Status (14)

Country Link
US (2) US20080248061A1 (pl)
EP (1) EP1926496B1 (pl)
JP (1) JP5106398B2 (pl)
KR (1) KR101347503B1 (pl)
CN (1) CN101277717A (pl)
AU (1) AU2006289102C1 (pl)
BR (1) BRPI0615862A2 (pl)
CA (1) CA2620727C (pl)
DK (1) DK1926496T3 (pl)
ES (1) ES2425228T3 (pl)
PL (1) PL1926496T3 (pl)
RU (1) RU2389506C2 (pl)
UA (1) UA95458C2 (pl)
WO (1) WO2007028823A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
SI1833992T1 (sl) * 2004-12-30 2015-06-30 Boehringer Ingelheim Vetmedica, Inc. PCV2 imunogeni sestavki in postopki proizvodnje takšnih sestavkov
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP3320919B1 (en) 2005-12-29 2020-05-27 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
DK2371383T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
AU2007333857B2 (en) 2006-12-15 2014-05-15 Boehringer Ingelheim Animal Health USA Inc. Treatment of pigs with PCV2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2712006A1 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN101875941A (zh) * 2010-03-09 2010-11-03 胡文锋 一种人工改造合成的dORF2art基因及其编码的蛋白质
CA2804604C (en) 2010-07-08 2023-10-03 United Biomedical, Inc. Designer peptide-based pcv2 vaccine
CN101920012B (zh) * 2010-07-22 2012-12-12 普莱柯生物工程股份有限公司 利用家蚕生物反应器生产猪圆环病毒2型重组衣壳蛋白亚单位疫苗的方法及其产品
WO2012076623A1 (en) 2010-12-08 2012-06-14 Intervet International B.V. A method to quantify the amount of a biological substance in a sample and a kit for performing the method
EP2564869A1 (en) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
CN102352347A (zh) * 2011-10-14 2012-02-15 浙江诺倍威生物技术有限公司 Pcv2重组杆状病毒构建及其亚单位疫苗制备方法
CN102517331A (zh) * 2011-12-26 2012-06-27 武汉中博生物股份有限公司 一种猪圆环病毒2型亚单位疫苗及其制备方法和其应用
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN102978232B (zh) * 2012-08-23 2014-07-16 郑州后羿制药有限公司 一种IPTG诱导猪圆环病毒2型重组Cap蛋白表达的方法
BR102013001893B1 (pt) 2013-01-25 2022-01-25 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
DK2994162T3 (en) 2013-05-08 2021-06-21 Pharmgate Biologics Inc Vaccine for pcv2 og mycoplasma
KR101527832B1 (ko) * 2013-05-28 2015-06-11 대한민국 돼지써코바이러스 2형(pcv2)의 orf2 재조합 유전자, 전달 벡터, 재조합 배큘로바이러스, 돼지써코바이러스 2형(pcv2) 재조합 캡시드 단백질 및 그의 제조방법
RU2662685C2 (ru) * 2013-09-25 2018-07-26 Зоэтис Сервисиз Ллс Pcv2b дивергентная вакцинная композиция и способы её применения
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
KR20220083861A (ko) 2013-10-02 2022-06-20 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
CN104548083B (zh) * 2013-10-22 2019-05-07 洛阳赛威生物科技有限公司 一种疫苗组合物及其制备方法和应用
CN110354258A (zh) 2013-12-03 2019-10-22 英特维特国际股份有限公司 抗猪圆环病毒2型的疫苗
WO2015082457A1 (en) 2013-12-03 2015-06-11 Intervet International B.V. Vaccine against lawsonia intracellularis and porcine circovirus 2
US10568954B2 (en) 2014-12-11 2020-02-25 Intervet Inc. Process for ready-to-use PCV/M.Hyo combination vaccine
JP2019509302A (ja) 2016-03-23 2019-04-04 インターベット インターナショナル ベー． フェー． アルブミンを含むｐｃｖ２及びｐｒｒｓウイルス感染症に対する混合ワクチン
US11654191B2 (en) 2016-03-23 2023-05-23 Intervet Inc. Vaccine for intradermal application against PCV2 and PRRS virus infection
RU2018137034A (ru) 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
CN105785037B (zh) * 2016-03-30 2017-09-19 中国农业科学院兰州兽医研究所 猪圆环病毒2型抗体快速检测层析试纸条及制备方法
CA3058281A1 (en) 2017-04-13 2018-10-18 Intervet International B.V. Vaccines containing swine pathogens for associated non-mixed use
WO2019022463A2 (ko) * 2017-07-24 2019-01-31 (주)제이비바이오텍 면역원성시스템 및 이를 포함한 동물 백신
BR112020002006A2 (pt) 2017-08-03 2020-08-11 Intervet International B.V. vacina compreendendo uma proteína orf2 de pcv2 de genótipo 2b
ES2962449T3 (es) 2017-10-17 2024-03-19 Intervet Int Bv Expresión recombinante de la proteína ORF2 del PCV2b en células de insecto
CN112088013B (zh) 2018-03-26 2024-12-06 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
US20220323567A1 (en) 2019-09-12 2022-10-13 Intervet Inc. Combination vaccine for intradermal administration
CN115427072A (zh) 2020-04-20 2022-12-02 英特维特国际股份有限公司 预防性治疗猪的疫苗组合
WO2022090357A1 (en) 2020-10-29 2022-05-05 Intervet International B.V. Combination vaccine for protecting swine against various disorders
AR132581A1 (es) 2023-05-03 2025-07-16 Boehringer Ingelheim Vetmedica Gmbh Composición inmunógena útil para la autoadministración por cerdos
TW202508619A (zh) 2023-05-03 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 用於誘導免疫反應之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69015222T2 (de) * 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
PT835930E (pt) * 1996-10-09 2001-06-29 Akzo Nobel Nv Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations

Also Published As

Publication number Publication date
KR101347503B1 (ko) 2014-01-02
EP1926496B1 (en) 2013-06-26
US20110064765A1 (en) 2011-03-17
US20080248061A1 (en) 2008-10-09
KR20080042159A (ko) 2008-05-14
AU2006289102B2 (en) 2011-12-15
WO2007028823A1 (en) 2007-03-15
BRPI0615862A2 (pt) 2011-05-31
CN101277717A (zh) 2008-10-01
RU2008113763A (ru) 2009-10-20
DK1926496T3 (da) 2013-09-30
EP1926496A1 (en) 2008-06-04
RU2389506C2 (ru) 2010-05-20
UA95458C2 (ru) 2011-08-10
AU2006289102C1 (en) 2017-11-30
CA2620727C (en) 2015-06-16
JP2009507811A (ja) 2009-02-26
CA2620727A1 (en) 2007-03-15
ES2425228T3 (es) 2013-10-14
AU2006289102A1 (en) 2007-03-15
JP5106398B2 (ja) 2012-12-26
US8008001B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
PL1926496T3 (pl) Szczepionka przeciw PCV-2
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
ZA200804918B (en) Therapeutic vaccine
ZA200709518B (en) Vaccine composition
IL186600A0 (en) Novel vaccine formulations
GB0522765D0 (en) Combination vaccine manufacture
GB0513421D0 (en) Vaccines
ZA200709207B (en) Vaccine
GB0524409D0 (en) Vaccines
GB0805675D0 (en) Adjuvanted vaccine
GB0810662D0 (en) Vaccine
GB0515135D0 (en) Vaccine
GB0524408D0 (en) Vaccines
GB0504940D0 (en) Vaccine formulation
GB0516944D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB2443591B (en) Adjuvanted vaccine
GB0511203D0 (en) Vaccines
GB0526412D0 (en) Vaccine
GB0503000D0 (en) Anti-atheroma vaccine
GB0521164D0 (en) Vaccine
GB0513189D0 (en) Vaccine
GB0511475D0 (en) Vaccine
GB0526232D0 (en) Vaccine